---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-276404"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T10:31:55.937923+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# XOMA reports Q3 2022 net loss $4.2M; receives first VABYSMO royalty from Roche

## Summary
- Total revenues $0.5M, down from $0.9M in Q3 2021; milestone revenue in prior year period.
- Net loss $4.2M vs $4.4M year ago; cash $78.3M with no debt.
- First commercial payment received from Roche for VABYSMO (faricimab) in wAMD and DME: $0.5M.
- Received $2.5M milestone from Kuros after Regeneron's acquisition of Checkmate.
- Paid $3.0M milestone to Affitech triggered by EU approval of VABYSMO.

## SEC filing metadata
- accession: 0001193125-22-276404
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312522276404/0001193125-22-276404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312522276404/d347911d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-276404
- JSON: https://secwatch.observer/filing/0001193125-22-276404.json
- Plain text: https://secwatch.observer/filing/0001193125-22-276404.txt

## Key facts
- Earnings Releases
  XOMA Royalty Corp reported the quarter ended September 30, 2022 results: revenue $0.5 million, net income $4.2 million.
  - Period: the quarter ended September 30, 2022
  - Revenue: $0.5 million
  - Net income: $4.2 million
  - Result: reported results
  source text: XOMA recorded total revenues of $0.5 million for the third quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/791908/000119312522276404/0001193125-22-276404-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.